SCHEMBL743360

SCHEMBL743360

Cc1cccc(NC(=O)Nc2ccc(-c3c(C(=O)NCC(F)(F)F)cn4ncnc(N)c34)cc2Cl)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.38
KMT2A Q03164 1/20 0.38
KDR P35968 2/20 0.37
FLT3 P36888 2/20 0.37
KIT P10721 1/20 0.37
AURKB Q96GD4 6/20 0.37
AURKA O14965 5/20 0.37
NTRK2 Q16620 3/20 0.37
NTRK1 P04629 2/20 0.37
RAB9A P51151 2/20 0.36
GBA1 P04062 1/20 0.36
MAPT P10636 1/20 0.36
NPC1 O15118 1/20 0.36
IKBKB O14920 1/20 0.35
PDPK1 O15530 1/20 0.35
EGFR P00533 1/20 0.35
LCK P06239 1/20 0.35
FYN P06241 1/20 0.35
CDK1 P06493 1/20 0.35
LYN P07948 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL744854 0.92 FLT3 (0.38) FGFR1KDRFLT3KITAURKB
SCHEMBL741930 0.92 FGFR1 (0.37) FGFR1KDRFLT3KITAURKB
Bromide SCHEMBL741865 0.91 FLT3 (0.38) FGFR1KDRFLT3KITAURKB
Hydrochloric Acid SCHEMBL744245 0.91 FLT3 (0.38) FGFR1KDRFLT3KITAURKB
SCHEMBL742685 0.91 FGFR1 (0.46) FGFR1KMT2AKDRFLT3KIT
SCHEMBL742990 0.90 MAPK14 (0.40) FGFR1KMT2AKDRFLT3KIT
SCHEMBL743507 0.90 FLT3 (0.37) FGFR1KDRFLT3KITAURKB
Maleic Acid SCHEMBL765350 0.88 FLT3 (0.36) FGFR1KDRFLT3KITAURKB
Fumaric Acid SCHEMBL742961 0.88 FLT3 (0.36) FGFR1KDRFLT3KITAURKB
Fumaric Acid SCHEMBL765351 0.88 FLT3 (0.36) FGFR1KDRFLT3KITAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100273800-A1 PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE BAYER HEALTHCARE LLC 2010-10-28 US claimed
US-8138336-B2 Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase BAYER HEALTHCARE LLC (US) 2012-03-20 US disclosed
US-8138336-B2 Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase BAYER HEALTHCARE LLC (US) 2012-03-20 US disclosed
US-8138336-B2 Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase BAYER HEALTHCARE LLC (US) 2012-03-20 US disclosed
US-20100273800-A1 PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE BAYER HEALTHCARE LLC 2010-10-28 US disclosed
US-20100273800-A1 PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE BAYER HEALTHCARE LLC 2010-10-28 US disclosed
US-20100273800-A1 PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE BAYER HEALTHCARE LLC 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273800-A1 PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE AURKC, AURKA, PLK1 FGFR1 776/4885KMT2A 1101/4885KDR 1946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.